A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma

NCT04669171 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Follicular Lymphoma
Marginal Zone Lymphoma

Interventions

BIOLOGICAL: EO2463
DRUG: lenalidomide
BIOLOGICAL: rituximab

Sponsor

Enterome